Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma

Canadian Journal of Ophthalmology

Volumn 45, Issue 3, 2010, Pages 269-273

  Yeung, Sonia N ^a   Paton, Katherine E ^a   Waite, Christopher ^a   Maberley, David A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Avastin; Bevacizumab; Iris neovascularization; Melanoma; Proton therapy

Indexed keywords

BEVACIZUMAB; BRIMONIDINE; DORZOLAMIDE PLUS TIMOLOL; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTON; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLINDNESS; BLURRED VISION; CASE REPORT; CASE STUDY; CHOROID MELANOMA; COBALT THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ENUCLEATION; EYE DISEASE; EYE FUNDUS; EYE INJURY; FOLLOW UP; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS BLOOD VESSEL; IRIS DISEASE; IRIS NEOVASCULARIZATION; ISCHEMIC HEART DISEASE; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); OPHTHALMOSCOPY; PROTON RADIATION; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CHOROID NEOPLASMS; GLAUCOMA, NEOVASCULAR; INJECTION; IRIS; MEGAVOLTAGE RADIOTHERAPY; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RADIATION INJURIES; RADIATION RESPONSE; VASCULARIZATION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID NEOPLASMS; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; IRIS; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTONS; RADIATION INJURIES; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77953305692     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-259     Document Type: Article

References (22)

1. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547-1554
2. Foss AJ, Whelehan I, Hungerford JL, et al. Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 1997;81:748-754 (Pubitemid 27453581)
3. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120:1665-1671 (Pubitemid 36401801)
4. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003;55:867-880
5. Castro JR, Char DH, Petti PL, et al. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 1997;39:989-996
6. Munzenrider JE, Gragoudas ES, Seddon JM, et al. Conservative treatment of uveal melanoma: probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys 1988;15:553-558
7. Egan KM, Gragoudas ES, Seddon JM, et al. The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmology 1989;96:1377-82; discussion 1382-1383
8. Gragoudas ES, Marie Lane A. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am 2005;18:111-8, ix.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
11. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105:232-237
12. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-452
13. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007;35:494-496
14. Boyd SR, Tan DS, de Souza L, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002;86:440-447
15. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293
16. Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009;28:117-144
17. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116:921-926
18. Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008;28:964-968
19. Wen JC, McCannel TA. Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma. Curr Opin Ophthalmol 2009;20:200-204
20. Shields CL, Demirci H, Dai V, et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 2005;25:868-874
21. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. Arch Ophthalmol 2007;125:751-756 (Pubitemid 46919735)
22. Vásquez LM, Somani S, Altomare F, Simpson ER. Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma. Can J Ophthalmol 2009;44:106-107